Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 21, 2015; 21(19): 6082-6087
Published online May 21, 2015. doi: 10.3748/wjg.v21.i19.6082
Published online May 21, 2015. doi: 10.3748/wjg.v21.i19.6082
Severe Henoch-Schönlein purpura with infliximab for ulcerative colitis
Yang Song, Yan-Hong Shi, Chong He, Chang-Qin Liu, Jun-Shan Wang, Yu-Jie Zhao, Yan-Min Guo, Rui-Jin Wu, Xiao-Yue Feng, Zhan-Ju Liu, Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, China
Author contributions: Song Y and Shi YH contributed equally to this study; Liu ZJ and Liu CQ designed the study; Wang JS, Wu RJ and Zhao YJ collected the patients' clinical data; He C, Guo YM and Feng XY performed the experiments; Song Y and Shi YH analyzed the data and wrote the manuscript.
Supported by National Natural Science Foundation of China, No. 81270470.
Ethics approval: The study was reviewed and approved by the Hospital and University Review Committees for Medical Research.
Informed consent: All study participants, or their legal guardians, provided informed written consent prior to study enrollment.
Conflict-of-interest: The authors declared no conflict interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Zhan-Ju Liu, MD, PhD, Professor, Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, No. 301 Yanchang Road, Zhabei District, Shanghai 200072, China. liuzhanju88@126.com
Telephone: +86-21-66301164 Fax: +86-21-66303983
Received: November 23, 2014
Peer-review started: November 24, 2014
First decision: December 11, 2014
Revised: January 16, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: May 21, 2015
Processing time: 177 Days and 18.2 Hours
Peer-review started: November 24, 2014
First decision: December 11, 2014
Revised: January 16, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: May 21, 2015
Processing time: 177 Days and 18.2 Hours
Core Tip
Core tip: Infliximab (IFX) is effective in the management of ulcerative colitis (UC). Henoch-Schönlein purpura (HSP) appears as a dermatological adverse effect of IFX. However, extensive ecchymosis in old UC patients is rare. This report describes a case of HSP reaction, which resolved upon IFX withdrawal.